Drugs Containing Excipient (Inactive Ingredient) GLYCERYL 1-STEARATE

Generic drugs containing GLYCERYL 1-STEARATE excipient

Company	Ingredient	NDC	Excipient
Padagis Israel Pharmaceuticals Ltd	fluocinonide	45802-151	GLYCERYL 1-STEARATE
Quality Care Products LLC	fluocinonide	55700-718	GLYCERYL 1-STEARATE
Primary Pharmaceuticals Inc	fluocinonide 0.1% 120gm cream, 100% soft silicone roll	72275-704	GLYCERYL 1-STEARATE

Glyceryl 1-Stearate Market Dynamics, Financial Trajectory, Regulatory Status and Patent Risk

Last updated: August 29, 2026

Glyceryl 1-stearate is a pharmaceutical excipient used mainly as an emulsifier, consistency agent, lubricant, stabilizer and controlled-release matrix component. The commercial market is fragmented across pharmaceutical, food, cosmetics and industrial applications. Public companies rarely report glyceryl 1-stearate revenue separately, so market size and financial trajectory must be assessed through capacity, raw-material costs, grade mix, regional demand and supplier economics rather than audited product-level revenue.

Pharmaceutical demand is stable but relatively small compared with food and personal-care consumption. The strongest commercial opportunities are in high-purity grades, direct-compression excipients, lipid-based delivery systems, modified-release tablets, topical products and integrated excipient systems. The principal risks are substitution by other glycerides, price competition in standard grades, fatty-acid feedstock volatility, regulatory qualification costs and dependence on a limited number of qualified suppliers.

What is glyceryl 1-stearate and how is it used in pharmaceuticals?

Glyceryl 1-stearate is a monoester of glycerol and stearic acid. Commercial glyceryl monostearate products often contain a mixture of mono-, di- and triglycerides, with composition varying by manufacturing route, purification and specification. The terms glyceryl monostearate, glyceryl stearate and glyceryl 1-stearate are therefore not always interchangeable for regulatory or technical purposes.

Primary pharmaceutical functions

Function	Pharmaceutical application
Emulsifier	Creams, ointments, emulsions and lipid dispersions
Lubricant	Tablets and capsules, particularly lipid-containing formulations
Consistency agent	Semisolids, topical products and suppositories
Matrix former	Sustained-release tablets and lipid matrices
Stabilizer	Suspensions, emulsions and dispersible systems
Wetting and dispersion aid	Poorly soluble active pharmaceutical ingredients
Lipid excipient	Lipid-based formulations and drug-delivery systems

Glyceryl monostearate is generally selected for its hydrophobicity, melting behavior, interfacial activity and compatibility with other lipids. Performance depends on monoester content, free glycerol, acid value, iodine value, peroxide value, melting range, particle size and polymorphic form.

What is the pharmaceutical market size for glyceryl 1-stearate?

No authoritative public source reports a standalone global pharmaceutical market value for glyceryl 1-stearate. Most commercial market studies aggregate the material into broader categories such as fatty-acid esters, emulsifiers, pharmaceutical excipients or specialty lipids. Supplier filings also usually combine pharmaceutical sales with food, cosmetics and industrial applications.

The market should therefore be analyzed through three segments:

1. Standard glyceryl monostearate used in high-volume formulations.
2. High-purity and compendial grades used in regulated pharmaceutical manufacturing.
3. Engineered or co-processed excipient systems used in modified-release and lipid-based delivery.

Pharmaceutical-grade material commands a premium over technical and cosmetic grades because of documentation, traceability, microbiological control, residual-solvent control, change-control obligations and customer qualification requirements. The premium is highest when the supplier provides formulation support, regulatory packages and consistent physical performance.

Estimated market structure

Segment	Demand profile	Pricing power	Main buyers
Technical grade	High volume, low margin	Low	Industrial manufacturers
Food grade	High volume, moderate margin	Low to moderate	Food companies
Cosmetic grade	Moderate volume, moderate margin	Moderate	Personal-care manufacturers
Pharmaceutical grade	Lower volume, higher qualification burden	Moderate to high	Generic and branded drug manufacturers
Specialty lipid systems	Low volume, high technical value	High	Drug-delivery and CDMO companies

What is driving glyceryl 1-stearate demand?

Pharmaceutical demand is linked to formulation activity rather than to a single therapeutic franchise. The main growth drivers are:

Growing use of lipid-based delivery systems

Poor aqueous solubility remains a common development problem. Glyceryl monostearate and related glycerides can form part of self-emulsifying, self-microemulsifying, lipid matrix or solid-lipid systems. These applications can generate higher-value demand because developers purchase performance and reproducibility rather than commodity volume.

Modified-release oral dosage forms

Glyceryl monostearate can be used in hydrophobic matrices that slow water penetration and drug diffusion. Its utility depends on active ingredient loading, particle size, compression force, polymer combinations and release specifications. Competing materials include glyceryl behenate, hydrogenated vegetable oils, stearic acid, waxes, ethylcellulose and lipid-polymer blends.

Topical and semisolid formulations

The excipient is used in creams, lotions, ointments and emulsions. Demand tracks dermatology, consumer health and generic topical-product development. Cosmetic and pharmaceutical formulations may use similar chemistry, but pharmaceutical products require tighter documentation and manufacturing controls.

Generic-drug manufacturing

Glyceryl 1-stearate is relevant to generic manufacturers because excipient changes can affect dissolution, bioavailability, stability and physical properties. Once included in an approved formulation, substitution may require comparative testing, regulatory assessment or a post-approval change filing.

Regional pharmaceutical expansion

Demand is strongest in established manufacturing regions such as North America, Europe, China, India and Japan. India and China are important sources of both generic drug production and excipient supply. Europe remains important for compendial compliance and specialty formulation development.

How does the financial trajectory for glyceryl 1-stearate look?

The financial trajectory is likely to be steady rather than high-growth. Revenue growth depends on volume expansion, movement into pharmaceutical-grade products and price pass-through for feedstock costs. Product-level financial forecasts are not publicly auditable because suppliers generally do not disclose glyceryl 1-stearate sales separately.

Key financial variables

Variable	Effect on supplier economics
Stearic acid and palm-based feedstock prices	Direct effect on cost of goods
Energy and hydrogenation costs	Affects manufacturing cost
Pharmaceutical-grade purification	Raises cost but supports premium pricing
Customer qualification	Increases switching barriers
Multi-industry demand	Reduces dependence on pharmaceuticals
Freight and regional inventory	Affects delivered margin
Quality failures or recalls	Can materially impair customer retention
Regulatory documentation	Supports premium positioning

The standard-grade market is exposed to commodity pricing. Suppliers with vertically integrated fatty-acid production, regional manufacturing and broad product portfolios generally have stronger cost positions. Smaller suppliers can compete through flexibility, short lead times and customized specifications.

Likely revenue scenarios

Scenario	Market outcome	Financial effect
Base case	Low- to mid-single-digit volume growth, stable pharmaceutical demand	Gradual revenue growth with limited margin expansion
Upside case	Greater use in lipid delivery and specialty modified-release systems	Faster growth and improved specialty-grade margins
Downside case	Substitution, excess capacity or feedstock deflation	Flat revenue and margin compression

A supplier’s exposure to pharmaceutical glyceryl 1-stearate is more attractive when the product is sold as part of a formulation platform rather than as an isolated commodity. Technical support, regulatory files, compendial compliance and validated supply continuity can increase customer retention.

Which companies supply pharmaceutical-grade glyceryl 1-stearate?

The competitive landscape includes multinational excipient suppliers, specialty lipid manufacturers, oleochemical companies and regional producers. Common competitive groups include:

• Large excipient suppliers with pharmaceutical-grade portfolios.
• Oleochemical manufacturers producing glycerides from fatty acids and glycerol.
• Indian and Chinese suppliers serving generic-drug manufacturers.
• European suppliers focused on compendial and specialty grades.
• Contract manufacturers and distributors that package or qualify regional supply.

The relevant competitive comparison is not limited to price. Buyers evaluate:

• USP-NF, Ph. Eur. or other compendial conformity.
• Batch-to-batch monoester content.
• Residual solvents and elemental impurities.
• Microbial quality.
• Oxidative stability.
• Animal-origin and palm-origin declarations.
• TSE/BSE statements.
• Nitrosamine and genotoxic impurity controls where relevant.
• Manufacturing-site inspection history.
• Change-notification practices.
• Dual sourcing and supply continuity.

A supplier without a pharmaceutical-grade dossier may be unable to displace an incumbent even when its nominal price is lower.

What is the FDA regulatory status of glyceryl 1-stearate?

Glyceryl monostearate is an established excipient used in drug products, but FDA status is product-specific. The FDA Inactive Ingredient Database records excipient use by route, dosage form and maximum potency history. Inclusion in the database does not constitute blanket approval for every route, formulation or concentration (U.S. Food and Drug Administration, n.d.).

The relevant regulatory question is whether the proposed use is supported by prior human exposure, listed inactive-ingredient precedent, safety data and product-specific chemistry. Pharmaceutical developers must also establish that the material meets the drug product’s quality requirements.

Regulatory documentation typically required

• Certificate of analysis.
• Identity and assay testing.
• Monoester and diester profile.
• Acid value and saponification value.
• Melting range.
• Free glycerol and free fatty-acid limits.
• Water content.
• Peroxide value.
• Residual solvents.
• Elemental impurities.
• Microbiological limits.
• Stability data.
• Manufacturing-process description.
• Change-control and audit documentation.

For European products, excipient risk assessment and pharmaceutical quality documentation are evaluated under the applicable EU framework. The European Medicines Agency has emphasized formal risk assessment and control of excipients in medicinal products (European Medicines Agency, 2015).

What is the Orange Book status of glyceryl 1-stearate?

Glyceryl 1-stearate does not have an independent Orange Book listing because it is an excipient rather than an approved active pharmaceutical ingredient. The FDA Orange Book lists approved drug products and certain patents or exclusivity information associated with those products, not standalone excipient inventories (U.S. Food and Drug Administration, n.d.).

An excipient can still affect an Orange Book-listed drug through:

• Formulation patents.
• Composition-of-matter claims covering a drug product.
• Controlled-release architecture.
• Drug-excipient ratios.
• Manufacturing-process claims.
• Method-of-use patents that depend on a specific dosage form.

Those rights attach to the finished product or formulation, not to ordinary commercial glyceryl 1-stearate as an excipient.

What patents protect glyceryl 1-stearate formulations?

The base excipient is generally a mature oleochemical substance and is unlikely to provide broad standalone patent protection. Patent value usually arises from a specific formulation, delivery system, particle structure, ratio, process or therapeutic application.

Typical patent claim categories

• Sustained-release tablets containing glyceryl monostearate.
• Lipid-based formulations for poorly soluble drugs.
• Solid lipid nanoparticles or lipid microparticles.
• Topical emulsions with defined glyceride ratios.
• Suppositories with specific melting and release properties.
• Co-processed excipients containing glyceryl monostearate.
• Manufacturing processes that produce a defined polymorph or particle-size distribution.
• Drug-excipient compositions with a demonstrated dissolution or bioavailability advantage.

A freedom-to-operate review must distinguish the excipient itself from a formulation patent that uses it. The relevant search terms should include glyceryl monostearate, glyceryl 1-stearate, glyceryl stearate, mono- and diglycerides, lipid matrix, solid lipid carrier and controlled-release composition.

Do Paragraph IV challenges or biosimilar risks affect glyceryl 1-stearate?

There is no standalone Paragraph IV pathway for glyceryl 1-stearate. Paragraph IV certifications apply to patents listed for approved drug products in an Abbreviated New Drug Application context. A generic manufacturer may challenge a formulation patent that uses glyceryl monostearate, but the challenge concerns the drug product and its listed patent claims.

Biosimilar risk is also not directly applicable. Biosimilars are regulated biological products, while glyceryl 1-stearate is a small-molecule excipient. The indirect exposure is limited to excipient demand from manufacturers of biologics, injectables or topical products that use lipid or emulsion systems.

What manufacturing and intellectual-property barriers exist?

The main barriers are operational rather than basic composition-of-matter patents.

Manufacturing barriers

• Controlling ester composition.
• Maintaining consistent melting behavior.
• Managing polymorphism and crystallinity.
• Preventing oxidation.
• Controlling residual glycerol and free fatty acids.
• Meeting low-bioburden or sterile-manufacturing requirements where applicable.
• Maintaining traceability of palm, animal or synthetic feedstocks.
• Reproducing particle size and powder flow.

Intellectual-property barriers

Patent risk increases when a company sells a specialized grade with a defined physical structure or uses the excipient in a proprietary drug-delivery system. Trade secrets may protect reaction conditions, purification, crystallization and blending processes even when the base chemistry is off-patent.

The most material commercial barrier is often customer qualification. A formulation manufacturer may avoid changing suppliers because a new grade can alter dissolution, hardness, friability, emulsion stability or shelf life.

How does glyceryl 1-stearate compare with competing excipients?

Excipient	Relative strength	Common limitation
Glyceryl monostearate	Emulsification, lipid matrices, semisolids	Variable composition and polymorphism
Glyceryl behenate	Stronger hydrophobic matrix behavior	Higher cost and different release profile
Stearic acid	Low cost, widely available	Less versatile as an emulsifier
Hydrogenated vegetable oil	Robust tablet lubrication and matrix use	May require higher processing control
Ethylcellulose	Reliable polymeric sustained release	Different processing and solvent considerations
Polysorbates	Strong emulsification	Oxidation and degradation concerns
Lecithin	Natural lipid functionality	Batch variability and oxidation risk

Glyceryl 1-stearate is most defensible when the formulation requires a specific lipid behavior and the supplier can demonstrate reproducibility. It is less defensible in applications where stearic acid, hydrogenated oils or other glycerides can be substituted without changing product performance.

What generic launch risks exist for glyceryl 1-stearate-containing products?

Generic launch risk depends on the finished drug product, not on the excipient alone. Key risk factors include:

1. Whether the reference product relies on a patented lipid matrix.
2. Whether the formulation has narrow dissolution specifications.
3. Whether the excipient grade affects bioequivalence.
4. Whether the supplier is named or effectively required by the reference formulation.
5. Whether alternative grades have been qualified.
6. Whether the product is immediate-release, modified-release, topical or complex lipid-based.
7. Whether formulation patents remain enforceable in the launch jurisdiction.

Immediate-release products using ordinary glyceryl monostearate generally present lower IP risk. Modified-release and poorly soluble-drug formulations present higher formulation and bioequivalence risk.

What licensing deals and settlement agreements affect the market?

There is no widely recognized industry-wide licensing structure for ordinary glyceryl 1-stearate. Licensing and settlement agreements typically arise at the finished-drug level, particularly for controlled-release, lipid nanoparticle, long-acting or topical delivery technologies.

A supplier can create commercial leverage through:

• Exclusive pharmaceutical-grade distribution.
• Regional supply agreements.
• Co-development of a proprietary excipient system.
• Joint ownership of formulation data.
• Contract manufacturing with customer-specific specifications.
• Long-term purchase commitments.

These arrangements may restrict practical substitution even where no patent blocks the excipient itself.

What is the geographic outlook for glyceryl 1-stearate?

North America and Europe offer higher prices and stronger documentation requirements. India and China provide major volume growth and manufacturing capacity. Japan and South Korea remain important for high-quality pharmaceutical and specialty formulation supply.

Regional purchasing priorities differ:

Region	Principal market characteristic
United States	FDA documentation, supply continuity and customer qualification
European Union	Compendial compliance, excipient risk management and sustainability
India	Generic-drug volume and cost-sensitive procurement
China	Domestic manufacturing growth and export capacity
Japan	High quality consistency and supplier qualification
Latin America	Imported supply and distributor-led procurement

Geographic diversification is commercially important because fatty-acid feedstocks, shipping rates, trade restrictions and local regulatory inspections can affect delivered cost.

Key Takeaways

• Glyceryl 1-stearate is a mature excipient with stable pharmaceutical demand and broader food, cosmetic and industrial exposure.
• No reliable public source provides a standalone pharmaceutical market size or supplier revenue figure.
• The strongest growth opportunity is in high-purity grades, modified-release systems and lipid-based delivery.
• Standard grades face commodity pricing and substitution pressure.
• Pharmaceutical-grade suppliers gain value from regulatory documentation, consistent physical properties and qualified supply chains.
• Glyceryl 1-stearate has no independent Orange Book listing and no standalone Paragraph IV pathway.
• Patent risk generally concerns finished-drug formulations, delivery systems and manufacturing processes.
• Biosimilar risk is indirect and limited to demand from biologic formulations using lipid or emulsion technologies.
• Financial performance is driven primarily by feedstock costs, grade mix, qualification barriers and specialty formulation adoption.
• Generic launch risk is highest for modified-release and complex lipid-based products.

FAQs About Glyceryl 1-Stearate

Is glyceryl 1-stearate the same as glyceryl monostearate?

Not always. Glyceryl monostearate may refer to a commercial mixture containing mono-, di- and triglycerides, while glyceryl 1-stearate identifies a specific monoester configuration. Regulatory specifications must be reviewed before treating the terms as equivalent.

Is glyceryl 1-stearate an active pharmaceutical ingredient?

No. It is an excipient used to modify formulation performance, including emulsification, lubrication, consistency and drug release.

Can glyceryl 1-stearate be replaced without a new drug application?

Replacement depends on the dosage form, formulation role, regulatory pathway and effect on product quality. A supplier or grade change may require comparative dissolution, stability, process validation or a post-approval regulatory filing.

Does glyceryl 1-stearate have strong patent protection?

The base excipient is a mature substance with limited standalone patent leverage. Stronger patents may cover specific drug-excipient ratios, lipid systems, controlled-release formulations or manufacturing processes.

Which quality attributes matter most when buying pharmaceutical-grade glyceryl 1-stearate?

The most important attributes are monoester content, melting range, acid value, peroxide value, particle size, polymorphic profile, residual solvents, microbial quality, traceability and change-control performance.

References

European Medicines Agency. (2015). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. https://www.ema.europa.eu/

United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

International Pharmaceutical Excipients Council. (2020). The joint IPEC-PQG good manufacturing practices guide for pharmaceutical excipients. International Pharmaceutical Excipients Council.